|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Hyperparathyroidism, secondary to renal failure |
| |
|
|
SIDE EFFECTS:
|
|
Bone pain |
|
constipation |
|
diarrhea |
|
drowsiness |
|
dryness of mouth |
|
headache, continuing |
|
increased thirst |
|
increase in frequency of urination, especially at night, or in amount of urine |
|
loss of appetite |
|
metallic taste |
|
muscle pain |
|
nausea or vomiting |
|
unusual tiredness or weakness |
|
Bone pain |
|
cloudy urine |
|
conjunctivitis |
|
decreased libido |
|
ectopic calcification |
|
high fever |
|
high blood pressure |
|
increased sensitivity of eyes to light or irritation of eyes |
|
irregular heartbeat |
|
itching of skin |
|
lethargy |
|
loss of appetite |
|
muscle pain |
|
nausea or vomiting and pancreatitis |
|
psychosis, overt |
|
rhinorrhea |
|
weight loss |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
>> Arteriosclerosis |
|
>> Cardiac function impairment |
|
>> Hyperphosphatemia |
|
>> Hypersensitivity to effects of vitamin D |
|
>> Renal function impairment |
|
Sarcoidosis, and possibly other granulomatous diseases |
|
|
ADULT DOSE:
|
|
Note: The currently accepted target range for iPTH levels in chronic renal failure patients is no more than 1.5 to 3 times the non-uremic upper limit of normal.
Antihyperparathyroid-
Initial: Intravenous (rapid), 0.04 mcg/kg to 0.1 mcg/kg (2.8 mcg to 7 mcg) administered no more frequently than every other day at anytime during dialysis.
Maintenance: Intravenous (rapid), if a satisfactory response is not observed, the dose may be increased by 2 mcg to 4 mcg at 2 to 4 week intervals. If an elevated calcium (Ca) level, or a calcium-phosphorus (Ca ´ P) product is greater than 75 is noted, drug dosage should be immediately reduced or interrupted until levels are normalized, and reinitiated at a lower dose.
Note: Paricalcitol doses may need to be decreased as the PTH levels decrease in response to therapy. Incremental dosing must be individualized.
Suggested Dosing Guidelines
PTH Level Paricalcitol Dose
the same or increasing increase
decreasing by <30% increase
decreasing by >30%, <60% maintain
decreasing by >60% decrease
1.5 to 3.0 times the upper limit maintain
of normal |
|
MAXIMUM ADULT DOSE:
|
|
Doses as high as 0.24 mcg/kg (16.8 mcg) have been safely administered.
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established.
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|